Abstract：
Triple-negative breast Cancer (TNBC) is one of the deadliest types, making up about 20% of all breast cancers. Chemotherapy is the traditional manner of progressed TNBC treatment; however, it has a short-term result with a high reversibility pace. The lack of targeted treatment limited and person-dependent treatment options for those suffering from TNBC cautions to be the worst type of cancer among breast cancer patients. Consequently, appropriate treatment for this disease is considered a major clinical challenge. Therefore, various treatment methods have been developed to treat TNBC, among which chemotherapy is the most common and well-known approach recently studied. Although effective methods are chemotherapies, they are often accompanied by critical limitations, especially the lack of specific functionality. These methods lead to systematic toxicity and, ultimately, the expansion of multidrug-resistant (MDR) cancer cells. Therefore, finding novel and efficient techniques to enhance the targeting of TNBC treatment is an essential requirement. Liposomes have demonstrated that they are an effective method for drug delivery; however, among a large number of liposome-based drug delivery systems annually developed, a small number have just received authorization for clinical application. The new approaches to using liposomes target their structure with various ligands to increase therapeutic efficiency and diminish undesired side effects on various body tissues. The current study describes the most recent strategies and research associated with functionalizing the liposomes\' structure with different ligands as targeted drug carriers in treating TNBCs in preclinical and clinical stages.
摘要：
三阴性乳腺癌（TNBC）是最致命的类型之一，占所有乳腺癌的20%。化疗是进展的TNBC治疗的传统方式;然而，它具有高可逆性步伐的短期结果。对于患有TNBC的患者，缺乏靶向治疗有限且依赖人的治疗选择，这警告说这是乳腺癌患者中最严重的癌症类型。因此,这种疾病的适当治疗被认为是一项重大的临床挑战.因此,已经开发了各种治疗方法来治疗TNBC，其中化疗是最近研究的最常见和众所周知的方法。虽然有效的方法是化疗，它们往往伴随着严重的限制，特别是缺乏特定的功能。这些方法会导致系统毒性，最终,多药耐药（MDR）癌细胞的扩增。因此,寻找新颖有效的技术来增强TNBC治疗的靶向性是必不可少的。脂质体已经证明它们是一种有效的药物递送方法；然而，在每年开发的大量基于脂质体的药物递送系统中，少数刚刚获得临床应用授权。使用脂质体的新方法用各种配体靶向其结构以提高治疗效率并减少对各种身体组织的不期望的副作用。目前的研究描述了在临床前和临床阶段与用不同配体作为靶向药物载体功能化脂质体结构相关的最新策略和研究。
